Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Colorectal cancer in 2012

Revisiting landmark trials and identifying new therapies

Nature Reviews Clinical Oncology volume 10, pages 71–72 (2013)Cite this article

Subjects

In the past year, long-term follow-up of trials have confirmed and disproved paradigms in the treatment of colorectal cancer, and identified a chemoprevention agent. In metastatic disease, chemotherapy in unresected primary tumours was studied, and randomized phase III trials introduced new therapy options. Molecular characterization of colon and rectal tumours offers new drug targets.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081–2087 (2011).

    Article  Google Scholar 

  2. Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol. 30, 1926–1933 (2012).

    Article  CAS  Google Scholar 

  3. Tournigand, C. et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J. Clin. Oncol. 30, 3353–3360 (2012).

    Article  CAS  Google Scholar 

  4. Sanoff, H. K. et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J. Clin. Oncol. 30, 2624–2634 (2012).

    Article  Google Scholar 

  5. Poultsides, G. A. et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receving combination chemotherapy without surgery as initial treatment. J. Clin. Oncol. 27, 3379–3384 (2009).

    Article  Google Scholar 

  6. McCahill, L. E. et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J. Clin. Oncol. 30, 3223–3228 (2012).

    Article  CAS  Google Scholar 

  7. Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499–3506 (2012).

    Article  CAS  Google Scholar 

  8. Arnold, D. et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study) [abstract]. J. Clin. Oncol. 30 (Suppl.), aCRA3503 (2012).

    Article  Google Scholar 

  9. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/S0140-6736(12)61900-X.

  10. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 300 West 10th Avenue, Columbus, 43210-1280, OH, USA

    Christina Wu & Richard M. Goldberg

Authors
  1. Christina Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard M. Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard M. Goldberg.

Ethics declarations

Competing interests

R. M. Goldberg receives research support from Sanofi and Bayer, and honoraria from Eli Lilly and Fresenius Kabi. C. Wu declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, C., Goldberg, R. Revisiting landmark trials and identifying new therapies. Nat Rev Clin Oncol 10, 71–72 (2013). https://doi.org/10.1038/nrclinonc.2012.227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.227

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing